Wakamoto Pharmaceutical Co.,Ltd. (4512.T)
JPY 231.0
(0.87%)
JPY 231.0
(0.87%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 570.97 Million JPY | -76.9% |
| 2022 | 575.8 Million JPY | 18.45% |
| 2021 | 755.51 Million JPY | 556.36% |
| 2020 | -218.12 Million JPY | 72.6% |
| 2019 | -442.18 Million JPY | -515.39% |
| 2018 | 243.09 Million JPY | -76.71% |
| 2017 | 704.38 Million JPY | -41.02% |
| 2016 | 851.64 Million JPY | -12.82% |
| 2015 | 884.47 Million JPY | -13.24% |
| 2014 | 1.01 Billion JPY | -8.27% |
| 2013 | 2.09 Billion JPY | 9.81% |
| 2012 | 1.26 Billion JPY | 27.0% |
| 2011 | 909.7 Million JPY | 19.56% |
| 2010 | 605.72 Million JPY | -26.28% |
| 2009 | 880.14 Million JPY | 18.96% |
| 2008 | 1.16 Billion JPY | -41.53% |
| 2007 | 1.12 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 11.25 Million JPY | -87.96% |
| 2023 Q1 | -28.4 Million JPY | -124.96% |
| 2023 FY | - JPY | -76.9% |
| 2023 Q4 | 172.53 Million JPY | 0.01% |
| 2023 Q3 | 172.52 Million JPY | 163.29% |
| 2023 Q2 | -272.59 Million JPY | -859.8% |
| 2022 Q3 | 154.72 Million JPY | 344.67% |
| 2022 FY | - JPY | 18.45% |
| 2022 Q4 | 113.79 Million JPY | -26.45% |
| 2022 Q2 | -63.23 Million JPY | -3157.96% |
| 2022 Q1 | -1.94 Million JPY | -101.47% |
| 2021 Q3 | 96.48 Million JPY | 176.04% |
| 2021 FY | - JPY | 556.36% |
| 2021 Q4 | 131.7 Million JPY | 36.5% |
| 2021 Q1 | -23.39 Million JPY | 83.78% |
| 2021 Q2 | -126.88 Million JPY | -442.3% |
| 2020 Q3 | 80.53 Million JPY | 122.27% |
| 2020 Q2 | -361.58 Million JPY | -101.95% |
| 2020 Q1 | -179.04 Million JPY | -105.1% |
| 2020 Q4 | -144.29 Million JPY | -279.16% |
| 2020 FY | - JPY | 72.6% |
| 2019 Q1 | -232.15 Million JPY | 50.38% |
| 2019 FY | - JPY | -515.39% |
| 2019 Q2 | -653.36 Million JPY | -181.43% |
| 2019 Q3 | 69.36 Million JPY | 110.62% |
| 2019 Q4 | -87.29 Million JPY | -225.86% |
| 2018 Q4 | -467.87 Million JPY | -451.57% |
| 2018 FY | - JPY | -76.71% |
| 2018 Q1 | 152.59 Million JPY | 243.78% |
| 2018 Q3 | 133.08 Million JPY | 173.7% |
| 2018 Q2 | -180.57 Million JPY | -218.34% |
| 2017 Q4 | -106.12 Million JPY | -181.66% |
| 2017 Q2 | -257.73 Million JPY | -270.55% |
| 2017 FY | - JPY | -41.02% |
| 2017 Q1 | 151.11 Million JPY | 1723.89% |
| 2017 Q3 | 129.96 Million JPY | 150.42% |
| 2016 FY | - JPY | -12.82% |
| 2016 Q1 | 132.86 Million JPY | 186.43% |
| 2016 Q3 | 165.85 Million JPY | 202.59% |
| 2016 Q2 | -161.66 Million JPY | -221.67% |
| 2016 Q4 | -9.3 Million JPY | -105.61% |
| 2015 Q3 | 180.42 Million JPY | 569.22% |
| 2015 Q4 | -153.73 Million JPY | -185.21% |
| 2015 FY | - JPY | -13.24% |
| 2015 Q1 | 147.34 Million JPY | 191.62% |
| 2015 Q2 | -38.45 Million JPY | -126.1% |
| 2014 Q4 | -160.81 Million JPY | -143.17% |
| 2014 FY | - JPY | -8.27% |
| 2014 Q3 | 372.5 Million JPY | 1523.24% |
| 2014 Q2 | 22.94 Million JPY | 68.18% |
| 2014 Q1 | 13.64 Million JPY | 133.0% |
| 2013 Q3 | 392.22 Million JPY | 1458.46% |
| 2013 Q4 | -41.35 Million JPY | -110.54% |
| 2013 FY | - JPY | 9.81% |
| 2013 Q1 | 77.89 Million JPY | -61.88% |
| 2013 Q2 | -28.87 Million JPY | -137.07% |
| 2012 Q3 | 242.95 Million JPY | 199.11% |
| 2012 Q4 | 204.34 Million JPY | -15.89% |
| 2012 FY | - JPY | 27.0% |
| 2012 Q1 | 18.29 Million JPY | 124.21% |
| 2012 Q2 | -245.12 Million JPY | -1439.71% |
| 2011 FY | - JPY | 19.56% |
| 2011 Q1 | -133.94 Million JPY | -141.73% |
| 2011 Q2 | -70.94 Million JPY | 47.04% |
| 2011 Q3 | 65.83 Million JPY | 192.8% |
| 2011 Q4 | -75.56 Million JPY | -214.78% |
| 2010 FY | - JPY | -26.28% |
| 2010 Q2 | -80.57 Million JPY | -154.28% |
| 2010 Q1 | 148.45 Million JPY | 10.81% |
| 2010 Q3 | 274.94 Million JPY | 441.23% |
| 2010 Q4 | 320.98 Million JPY | 16.74% |
| 2009 Q4 | 133.97 Million JPY | -62.85% |
| 2009 Q1 | 50.71 Million JPY | 883.12% |
| 2009 FY | - JPY | 18.96% |
| 2009 Q2 | 353.12 Million JPY | 596.24% |
| 2009 Q3 | 360.64 Million JPY | 2.13% |
| 2008 Q4 | 5.15 Million JPY | -98.08% |
| 2008 Q3 | 268.82 Million JPY | 612.49% |
| 2008 Q2 | 37.73 Million JPY | 0.0% |
| 2008 FY | - JPY | -41.53% |
| 2007 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | 90.517% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 99.935% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 100.203% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 99.694% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 98.427% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | 95.345% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 99.446% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | 55.841% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | 96.887% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | 93.637% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | 84.442% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | 59.303% |
| Tsumura & Co. | 30.77 Billion JPY | 98.145% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 96.95% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | 89.168% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 98.393% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | 91.703% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | 96.741% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | 94.454% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 115.226% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | 92.44% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | 179.968% |
| MedRx Co., Ltd | -884.51 Million JPY | 164.552% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | 89.687% |
| Solasia Pharma K.K. | -635 Million JPY | 189.917% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 124.052% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | 93.769% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 98.452% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | 206.072% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 97.791% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | 88.808% |